InspireMD (NSPR)
(Delayed Data from NSDQ)
$2.00 USD
+0.09 (4.44%)
Updated Apr 26, 2024 03:23 PM ET
After-Market: $1.94 -0.06 (-3.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Price, Consensus and EPS Surprise
NSPR 2.00 +0.09(4.44%)
Will NSPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NSPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NSPR
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
Down -24.61% in 4 Weeks, Here's Why InspireMD, Inc. (NSPR) Looks Ripe for a Turnaround
NSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Other News for NSPR
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
InspireMD Boosts Executive Severance Benefits Ahead of Potential Takeover
InspireMD to Present Key Trial Results at LINC 2024
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
InspireMD announces abstract one-year follow-up results from C-GUARDIANS trial